explore -WSS

explore

author：hotspot 2025-09-28 02:31:22 - browse：67985

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： The cancer stories no one wants to hear

WSS

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Cassava Sciences’ Alzheimer’s clinical trials should be halted

CDC recommends RSV monoclonal antibody for infants

CDC recommends RSV monoclonal antibody for infants

FDA clears Verve to begin U.S. study of gene

FDA approves Sage Therapeutics’ rapid

entertainment

explore

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

STAT Readout Newsletter: Biotech news today

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA clears Verve to begin U.S. study of gene

Hepatitis C has a cure — but many Americans still lack access to it

Roche acquires Telavant from Roivant, adding experimental IBD treatment

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

ADCs take center stage as promising cancer treatments

Bright Health sells Medicare Advantage business to Molina

The cancer stories no one wants to hear

hotspot

FDA clears Verve to begin U.S. study of gene

Merck, Daiichi strike cancer drug pact worth up to $22 billion

The cancer stories no one wants to hear

FDA clears Verve to begin U.S. study of gene

Chris Christie meets with Zelenskyy during Ukraine trip

The problems with dementia villages

hotspot

entertainment

hotspot

focus